A multimedia educational report for HCPs managing liver cancer patients
Access this scientific summary report to enhance your knowledge and understanding of the current landscape of hepatocellular carcinoma (HCC) treatment and emerging therapies that could offer the possibility for individualized treatment.
Videos and written summaries of presentations from liver cancer experts Andrew Zhu, Peter Galle, and Richard Finn survey current standards of care and new treatment strategies for HCC. The report includes case studies to illustrate how to translate evidence into practice.
- HCC pathophysiology and diagnosis, including tumor–microenvironment interactions
- Optimal sequencing of TKIs and immunotherapy
- The challenges of 3rd line HCC treatment and beyond
- TKI and immunotherapy combination approaches
The presentations took place at an independent satellite symposium at ILCA 2019. Access the symposium details and take-home messages from the Faculty.
You can also watch the full webcast of the symposium.
Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center.
He is an internationally recognized expert in hepatocellular carcinoma and cholangiocarcinoma.
Director of the Internal Medicine Department in Mainz, Germany.
He is an expert in apoptotic cell death in the liver, immune escape of tumor cells, and the clinical and molecular aspects of HCC.
Professor of Clinical Medicine at the Geffen School of Medicine, UCLA, USA, and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, UCLA, USA.
He is an expert in translating molecular understanding into novel target therapies for hepatobiliary cancers.
This activity is supported by an education grant from Eli Lilly and Company.
Springer Healthcare IME.
The Campus, 4 Crinan Street
London, N1 9XW, UK
Telephone +44 (0) 203 192 2023
Header Img, ILCA SS cover, New Content Item, Andrew Zhu, Peter Galle, Richard Finn